Cellebrite DI Lowers FY2026 Sales Guidance from $565.000M-$571.000M to $555.000M-$561.000M vs $568.048M Est

Benzinga Newsdesk www.benzinga.com Negative 95.4%

Neg 95.4% Neu 0% Pos 0%

Cellebrite DI (NASDAQ:CLBT) lowers FY2026 sales outlook from $565.000 million-$571.000 million to $555.000 million-$561.000 million vs $568.048 million estimate.